NCT02819960 2022-12-14
Prevention of Irinotecan Induced Diarrhea by Probiotics
S&D Pharma SK s.r.o.
Phase 3 Completed
Clinical Trials
11 trialsNCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00040391 2016-12-01
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Celgene Corporation
Phase 2 Terminated
NCT00582426 2015-05-04
LARCID
Novartis
Phase 3 Completed
NCT01543451 2014-03-26
Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea
Helsinn Healthcare SA
Phase 2 Completed
NCT01410955 2014-01-23
Prevention of Irinotecan Induced Diarrhea by Probiotics
Monsea Ltd.
Phase 3 Completed
NCT01739634 2012-12-03
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Salient Pharmaceuticals Incorporated
Phase 1/2 Unknown
NCT00006269 2012-05-25
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Novartis
Phase 3 Terminated
NCT00050635 2009-11-19
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Novartis
Phase 4 Completed
NCT00036517 2005-06-24
Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
PhytoCeutica
Phase 1/2 Terminated